echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > NICE recommends Koselugo for neurofibromatosis type 1

    NICE recommends Koselugo for neurofibromatosis type 1

    • Last Update: 2022-05-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca and MSD's Koselugo (selumetinib) for use in the UK NHS


    child

    NF1 is a debilitating genetic disorder with a prevalence of 1 in 4,000 people


    Koselugo works by blocking specific enzymes -- mitogen-activated protein kinase kinases 1 and 2 (also known as MEK 1 and MEK2) that are involved in stimulating cell growth


    An open-label phase II trial determined the clinical benefit of selumetinib in patients with plexiform neurofibromas


    As of March 29, 2019, a total of 34 patients (68%) had confirmed partial responses, of which 28 had durable responses (lasting ≥1 year)


     

    Original source:

    Original source:

    https:// href="https://" target="_blank" rel="noopener">https:// https:// 



    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.